At present, diabetes is one of the most important chronic noncommunicable diseases, that have threatened human health. By 2020, the number of diabetic patients worldwide has reached 425 million. This amazing number has attracted the great attention of various countries. With the progress of computing technology, many mathematical models and intelligent algorithms have been applied in different fields of health care. 822 subjects were selected in this paper. They were divided into 389 diabetic patients and 423 nondiabetic patients. Each of the subjects included 41 indicators. Too many indicator variables would increase the computational effort and there could be a strong correlation and data redundancy between the data. Therefore, the sample features were first dimensionally reduced to generate seven new features in the new space, retaining up to 99.9% of the valid information from the original data. A diagnostic and classification model for diabetes clinical data based on recurrent neural networks were constructed, and particle swarm optimization (PSO) was introduced to optimise recurrent neural network's hyperparameters to achieve effective diagnosis and classification of diabetes.
目的 探讨血清可溶性PD-1 (sPD-1)水平与2型糖尿病(T2DM)患者颈动脉粥样硬化斑块的关系.方法 选择2016年10月～2019年3月广西壮族自治区南宁市第一人民医院收治的T2DM患者100例,按照是否存在颈动脉粥样硬化斑块,将其分为斑块组(54例)和无斑块组(46例).比较两组患者一般资料、生化指标以及血清sPD-1水平和颈动脉Crouse积分,多因素分析采用logistic回归分析.结果 斑块组收缩压水平和吸烟、饮酒人数占比高于无斑块组(P＜0.05).斑块组C反应蛋白、三酰甘油水平高于无斑块组(P＜ 0.05).斑块组血清sPD-1水平和颈动脉Crouse积分高于无斑块组(P＜0.05),且血清sPD-1水平和颈动脉Crouse积分呈正相关(r=0.384,P=0.023).多因素logistic回归分析显示吸烟、饮酒、C反应蛋白、sPD-1均是T2DM患者颈动脉粥样硬化斑块形成的独立危险因素(P＜0.05).ROC曲线显示sPD-1临界值为1.41 ng/mL,曲线下面积为0.824,敏感度为81.24％,特异性为78.79％(95％CI:0.669～0.979,P=0.027).结论 血清sPD-1水平升高均可能增加T2DM患者颈动脉粥样硬化斑块形成的风险,监测血清sPD-1水平可以用于诊断颈动脉粥样硬化斑块.
目的 观察重组甘精胰岛素与格列美脲联合治疗2型糖尿病的疗效.方法 选取2016年2月～2017年2月收治的2型糖尿病患者126例为研究对象,随机分为对照组和观察组各63例.对照组给予精蛋白生物合成人胰岛素联合格列美脲治疗,观察组给予重组甘精胰岛素与格列美脲治疗,观察治疗前后两组空腹血糖(FPG)、 餐后2h血糖(2hPG)、血糖总体达标时间、糖化血红蛋白(HBA1c)、胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)等指标的差异及治疗期间低血糖发生率.结果 治疗后,观察组FPG、2hPG、HBA1c、血糖总体达标时间、HOMA-IR、低血糖发生率均明显低于对照组(P<0.05);HOMA-β高于对照组(P<0.05).结论 重组甘精胰岛素与格列美脲联合治疗2型糖尿病可有效将血糖控制在正常范围,改善胰岛功能,减少低血糖发生率,安全、有效.
